Vakzinehersteller mit Gewinnpolster
May 11, 2021 -
Die vier führenden Vakzinehersteller sahen einen rasanten Anstieg ihrer Profite seit dem Rollout der Coronavirus Impfungen, noch verstärkt durch rund $18,5 Milliarden von Regierungen, öffentlichen und privaten Stellen.
In total, governments and not-for-profit organisations have provided $4.59 billion, according to science data analytics company Airfinity. Private funding has provided around $13.91 billion.
AstraZeneca/Oxford University has received over $11.5 billion, and Johnson & Johnson has scooped up $1.1 billion. Almost $3.2bn has gone to Pfizer/BioNTech, while Moderna has received $2.68 billion.
Pfizer expects 2021 revenue of between $44 billion and $46 billion, with profits of at least $14 billion, split 50-50 between Pfizer and its German partner BioNTech.
Moderna’s forecast for 2021 is for revenue of $16 billion, overwhelmingly from vaccine sales.
Johnson & Johnson has said it will provide the vaccine on a not-for-profit basis as long as the world continues suffering from the pandemic. However, even after the pandemic has passed, people will need to receive booster shots to protect themselves from new variants.